BioSpace News Archive

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in the “Novel Oncology Targets” panel at the Cowen 42nd Annual Health Care Conference.

Endo International plc reported financial results for the fourth-quarter and full-year ended December 31, 2021 and introduced first-quarter 2022 financial guidance.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and twelve months ended Dec. 31, 2021.

Rising of prevalence of cancer worldwide, technological advances in cancer therapies, and new product launches are among the key factors driving the global Radiotherapy market revenue growth.

Increasing funds from public and private organizations, rising demand for vaccines and molecular therapy, and rapid advancements in biomedical technology are key factors expected to drive global Biologics market revenue growth.

Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, provided a corporate update and reported fourth quarter and full year 2021 financial results.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results for the fourth quarter and year ended December 31, 2021, and provided operational updates.

Foghorn® Therapeutics Inc., a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced that Foghorn will participate on a panel at Cowen’s 42nd Annual Health Care Conference which is being held virtually March 7th through March 9th, 2022.

FibroGen, Inc. reported financial results for the fourth quarter and full year 2021 and provided an update on the company’s recent developments.

AVITA Medical, Inc. reported its financial results for the quarter ending December 31, 2021, and its transition period fiscal year from July 1, 2021, to December 31, 2021.